Aldosterone antagonism for HFpEF

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

Original languageEnglish (US)
Pages (from-to)244-246
Number of pages3
JournalNature Reviews Cardiology
Volume10
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Mineralocorticoid Receptor Antagonists
Aldosterone
Heart Failure
Morbidity
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Aldosterone antagonism for HFpEF. / Borlaug, Barry A.

In: Nature Reviews Cardiology, Vol. 10, No. 5, 05.2013, p. 244-246.

Research output: Contribution to journalArticle

@article{55319b6bdfa0456baaed83c20f59d520,
title = "Aldosterone antagonism for HFpEF",
abstract = "No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.",
author = "Borlaug, {Barry A}",
year = "2013",
month = "5",
doi = "10.1038/nrcardio.2013.51",
language = "English (US)",
volume = "10",
pages = "244--246",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Aldosterone antagonism for HFpEF

AU - Borlaug, Barry A

PY - 2013/5

Y1 - 2013/5

N2 - No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

AB - No therapy has been proven to reduce morbidity and mortality in patients with heart failure and preserved ejection fraction (HFpEF). Owing to the deleterious cardiovascular effects of aldosterone, mineralocorticoid antagonists hold promise to treat this disorder. The Aldo-DHF trial provides valuable insights into the effects of these agents in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=84876938139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876938139&partnerID=8YFLogxK

U2 - 10.1038/nrcardio.2013.51

DO - 10.1038/nrcardio.2013.51

M3 - Article

C2 - 23546445

AN - SCOPUS:84876938139

VL - 10

SP - 244

EP - 246

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 5

ER -